Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Gemcitabine and Cisplatin in Bladder Cancer
NCT02989584Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2016
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in bladder cancer and urothelial carcinoma (UC) (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicity Rate at 5 years. Started Dec 2016; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
bladder cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02989584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989584.